AREG mAb synergism with DNA-damaging agents was also observed in mice implanted with prostate or breast cancer cells together with AREG-expressing stromal cell counterparts, wherein an AREG mAb combined with mitoxantrone, reduced tumor volume more significantly than either monotherapy alone [100]. This evidence concerns the gene AREG and neoplasm.